Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial
JAMA Oncol 2023 Apr 06;[EPub Ahead of Print], C Tang, AD Sherry, C Haymaker, T Bathala, S Liu, B Fellman, L Cohen, A Aparicio, AJ Zurita, A Reuben, E Marmonti, SG Chun, JP Reddy, A Ghia, S McGuire, E Efstathiou, J Wang, J Wang, P Pilie, C Kovitz, W Du, SJ Simiele, R Kumar, Y Borghero, Z Shi, B Chapin, D Gomez, I Wistuba, PG CornFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.